A handful of tumor-derived cell lines form the mainstay of cancer therapeutic development, yielding drugs with an impact typically measured as months to disease progression. To develop more effective breast cancer therapeutics and more readily understand their clinical impact, we constructed a functional metabolic portrait of 46 independently derived breast cell lines. Our analysis of glutamine uptake and dependence identified a subset of triple-negative samples that are glutamine auxotrophs. Ambient glutamine indirectly supports environmental cystine acquisition via the xCT antiporter, which is expressed on one-third of triple-negative tumors in vivo. xCT inhibition with the clinically approved anti-inflammatory sulfasalazine decreases tumor growth, revealing a therapeutic target in breast tumors of poorest prognosis and a lead compound for rapid, effective drug development. Glucose Uptake (% increase at 4 hours) Cell Line B 0 50 (legend on next page) Cancer Cell
INTRODUCTION
Current cancer therapeutic development methodologies are expensive, slow, and unable to allow early prediction of the palette and prevalence of responses tumors can mount when challenged with a prototypic drug. Breast cancer is a challenging example. Large heterogeneity exists within and between wellestablished subtypes and drug responses (reviewed in Weigelt and Reis-Filho, 2009 ). Three distinct nomenclatures group breast tumors based on morphological criteria (e.g., ductal, lobular, invasive, or in situ); expression of the estrogen receptor (ER), progesterone receptor (PR), and Her2 receptor tyrosine kinase (Her2); or molecular phenotype, derived from comprehensive mRNA similarities (e.g., luminal, basal) . Approximately one-fourth of breast tumors are ''triple negative'' (ER À / PR À / Her2 À ; TNBC), and usually have a basal molecular phenotype. They are aggressive, with poorest prognosis, high mitotic index, and intrinsic DNA damage repair defects (reviewed in Weigelt and Reis-Filho, 2009; Alli et al., 2009) . A subset termed claudin low and related metaplastic tumors have rapid disease courses,
Significance
There is a strong disconnect between compound efficacy in tumor cell lines used for cancer drug development versus clinical response rates, slowing the production of effective therapeutics. This would be improved if the frequency and types of tumor responses to a particular perturbation could be identified early in the process. While drug target expression is currently used to identify applicable clinical populations, these patient cohorts contain both responders and nonresponders. Here, we use functional analyses in 47 independent breast-derived cell lines to measure metabolic responses related to perturbations in glutamine metabolism, and estimate their frequency. We identify a therapeutic target in a severely underserved population of patients with breast cancer and a lead compound for rapid, durable therapeutic development. Hs578t  M435  MCF7  M231  M10A  H1954  M468  184A1  H1569  M453  ZB  T47D  H38  HMLE  H1500  M361  184B5  BT474  LY2  M436  AU565  H1187  H3153  BT20  M175  H2185  H70  M157  M415  Z1  CAMA1  SKBR3  H1428  H1937  Z30  U812  H1143  BT483  600MPE  M134 stem cell features, and chemotherapy-resistant characteristics (Hennessy et al., 2009 , Prat et al., 2010 . No TNBC-targeted therapeutic exists, and patient prognosis is grim. Many tumors increase uptake and reliance on environmental nutrients such as glucose, glutamine (reviewed in Souba, 1993; Gatenby and Gillies, 2004; DeBerardinis et al., 2008) , cystine, and asparagine (Iglehart et al., 1977; Asselin et al., 1989) . Seminal work in tumor series of increasing proliferation rate and de-differentiation (Erlich ascites, Knox et al., 1970; Morris hepatoma, Linder-Horowitz et al., 1969; Nb2 lymphoma, Gout et al., 1997) correlated these features with malignant progression, fostering drug development efforts focused on specific nutrients. However, resulting nutrient mimetics were systemically toxic (reviewed in Souba, 1993) , and inexplicable variability among increasing numbers of tumor isolates eventually discouraged these endeavors. Only leukemia dependence on asparagine was successfully pursued to a molecular understanding and effective drug (Asparaginase, reviewed in Narta et al., 2007) .
The xCT cystine/glutamate antiporter is the major means of increasing cystine uptake and the rate-limiting step for glutathione (GSH) synthesis in fibroblasts, rat hepatocytes, and Nb2 lymphoma (Bannai and Tateishi, 1986; Gout et al., 1997) . Dual roles in reactive oxygen species (ROS) neutralization and detoxification of xenobiotics such as chemotherapeutics make GSH an appealing drug target. However, inhibitors of glutathione synthesis failed clinical trials due to toxicities related to systemic GSH depletion (reviewed in Hamilton and Batist, 2004) . xCT may provide a target for cell-specific GSH depletion. Drug screens identified off-target effects of the anti-inflammatory pro drug sulfasalazine (SASP) as an xCT inhibitor (Gout et al., 2001) . SASP, glutamate, monosodium glutamate, and chemical inhibitors of xCT reduce GSH, increase ROS, potentiate chemotherapeutic effects, and attenuate growth in a handful of tumorderived cell lines in vitro and xenografts (reviewed in Lo et al., 2008a) . SASP is labile and insoluble under physiological conditions, limiting anti-xCT use to preclinical experiments. Other effects ascribed to SASP include the on-target anti-inflammatory activity of an SASP metabolite, NFkB inhibition, and direct interaction with GSH in cell-free extracts.
Molecular explanations for glutamine reliance remain elusive, although the phenomenon is well described (Coles and Johnstone, 1962; Kovacevi c and Morris, 1972; Reitzer et al., 1979; DeBerardinis et al., 2007; Yuneva et al., 2007; Wise et al., 2008) . Glutamine provides carbon and nitrogen for independent metabolic events, either directly, (e.g., nucleotide and protein synthesis), via the de-amidated product glutamate (e.g., polysaccharide synthesis, membrane antiporter activities), or via further glutamate deamination to 2-ketoglutarate (2-kg; e.g., respiratory/tricarboxylic acid (TCA) cycle substrates; reviewed in DeBerardinis and Cheng 2010). Abundant serum levels maintained by skeletal muscle reserves allow most cells to be glutamine consumers, although they may also be capable of synthesis (reviewed in Curthoys and Watford, 1995; Kovacevic and McGivan 1983) . Glutaminase (GLS; GLS) and glutamine synthase (GS; GLUL) modulate intracellular glutamine/glutamate levels; GLS deamidates glutamine, producing glutamate and ammonia, while GS synthesizes glutamine from these products. Reciprocal expression precludes futile substrate cycling (Curthoys and Watford, 1995; Kovacevic and McGivan 1983) . GLS expression levels were correlated with proliferation rate, respiratory glutamine use, and environmental glutamine reliance (Knox et al., 1970; Linder-Horowitz et al., 1969; reviewed in Wise et al., 2008) . Thus GLS is a commonly proposed biomarker of glutamine-dependence and therapeutic target (Lobo et al., 2000; Lora et al., 2004; Wang et al., 2010 , Yuneva et al., 2007 van den Heuvel et al., 2012) , and GLUL a marker of glutamine independence (Collins et al., 1998; Kung et al., 2011) .
Resurgence of interest in nutrient reliance followed realizations that oncogenes can direct nutrient uptake and dependence (reviewed in Wise and Thompson, 2010) . However, as in other preclinical discoveries, findings in exemplar cell lines do not identify appropriate patient populations or estimate their sizes. For example, the metabolic effects of oncogenic Myc vary substantially between tissue types (Yuneva et al., 2012) , making a simple cause-effect relationship between oncogenic Myc and glutamine dependence unlikely. Nor does restricting expectations to tumors of one tissue type improve the probable efficacy; in singular glioma lines, oncogenic Myc confers glutamine reliance (Wise et al., 2008) , but studies of multiple glioma lines report little glutamine dependence (Dranoff et al., 1985) . Also, naturally arising tumors without a dominant oncogenic driver may overcome nutrient scarcity by switching nutrient sources (Zielke et al., 1978) , attenuating cell cycle progression (Jones et al., 2005) , or other activities reported in nontransformed cells. Finally, nutritional requirements of tumors versus proliferating normal cells, rather than quiescent tissues have seldom been reported (exceptions: Iglehart et al., 1977; Jelluma et al., 2006) , but are a critical part of the therapeutic development puzzle. Here we present analyses Figure S1 and Tables S1-S3. of metabolic activities implied by microarray data and identification of therapeutic targets enriched in basal and claudin low TNBC.
RESULTS
Expression profiles of culture-adapted, proliferating nontumorigenic cells (human mammary epithelial cell derivatives; HMECd); freshly purified normal breast epithelia; and purified tumor cells from patient pleural effusions were derived and merged with previously published expression profiles of 45 independently derived breast carcinoma cell lines (see Supplemental Experimental Procedures available online; Neve et al., 2006) . These represent all major breast cancer subtypes and common breast oncogenes in their natural genetic contexts ( Figure 1A ; Table  S1 ). Significance analysis contrasting purified tumors and tumor-derived cell lines against purified normal breast epithelia and HMECd lines identified about 760 differentially expressed probeset IDs (>30%) encoding metabolic proteins ( Figure S1A ; Table S2 ).
Nutrient Preference Varies Widely among Breast Tumors
Elevated glucose consumption relative to adjacent quiescent tissue is a canonical hallmark of tumors, but whether this is due to proliferative glycolytic demands or specific oncogenic activities is unclear. In analysis of in vitro glucose uptake rates by tumorigenic versus HMECd lines, we found highest glucose consumption in luminal carcinoma-derived isolates ( Figure 1B) . Claudin low TNBC and approximately one-third of basal samples consume as little or less glucose than HMECd, although they preserve many aspects of the aggressive tumors from which they are derived; (e.g., similar molecular signatures , rapid doubling times, ( Figure 1C ), and extracellular matrix invasiveness (Sommers et al., 1994 , Han et al., 2010 . Thus, glucose consumption varies widely among breast isolates, and tumorigenic lines do not necessarily consume more glucose than nontumorigenic proliferating cells. Glutamine is an alternate bioenergetic substrate for many metabolic processes. In amino acid depletion analyses, we found that most basal and claudin low TNBC consume more glutamine than the luminal or HMECd samples ( Figure 1D ). However, at least four claudin low TNBC consume little glutamine (black triangles) and do not significantly increase consumption of another amino acid over that of the HMECd lines, with the possible exception of cystine ( Figure 1E ). Thus while nutrient preference often associates with molecular phenotype, the four claudin low exceptions reveal this as a generalization. Significantly enhanced nutrient consumption may not be an absolute requisite of aggressive breast tumors.
Reduced hGAC Expression Identifies Luminal Breast Carcinomas
We tested historical associations between glutamine consumption and glutaminase expression in our cells. Probeset IDs targeting most portions of GLS (p = 0.6, 0.9, and 0.4), and total GLS protein levels ( Figure S1B , p = 0.19) are not statistically different between tumor molecular subtypes. However, a GLS carboxy terminal splice variant (hGAC) is reduced in luminal carcinomas ( Figure 1F ; hGAC: 221510_s_at; p = 3.1 3 10 À9 ; Elgadi et al., 1999;  Figure S1C ). hGAC, but not other GLS probeset ID signals, are also lower in ER + and luminal tumors compared to ER À and basal tumors in eight of eight clinical breast tumor microarrays examined ( Figure 1G ; Table S3 ). Thus reduced hGAC expression is a strong indicator of luminal carcinoma identity (t test luminal versus all p = 4.1 3 10 À13 ). While hGAC expression and glutamine consumption modestly correlate ( Figure 1F , p = 0.005), the exceptions in our panel (black icons between dotted vertical lines) reveal that hGAC and GLS probeset IDs poorly identify high glutamine consumers.
Glutamine Restriction Slows Expansion of Most Breast Cell Lines
Comparison of glutamine restriction responses between tumorigenic and HMECd samples revealed that 68% of luminal and 54% of basal TNBC samples were more restriction-resistant than HMECd (Figure 2A ). Restriction deficits were not rescued by increasing the glucose concentration 2-or 5-fold ( Figure 2B , 23 glucose; 53 not shown), suggesting that cells do not simply switch nutrients like fibroblasts and Erlich ascites (Zielke et al., 1978; Kvamme and Svenneby, 1961) to exhaust media glucose. Growth curves of HMECd and similarly sensitive tumor lines revealed that glutamine restriction simply slows culture expansion of each cell type (Figure 2A , examples at arrows; Figure 2C ; Figure S2A ). Unlike glucose restriction, glutamine restriction produces little AMPK activation (T-172 phosphorylation) indicative of ATP depletion, and little ACC phosphorylation that would inhibit fatty acid synthesis ( Figure 2D ). Only a modest increase in cell number/ATP ratios ( Figure 2C Figure 2E ). Culture confluence reduces S-phase fractions and glutamine sensitivity, indicating that proliferative drive imparts glutamine reliance ( Figure 2E C versus CF, percent S-phase; Figure 2F ). These data predict that normal proliferating breast progenitors and most breast tumors would survive a glutamine-restricting therapeutic by simply slowing expansion rates. Glutamine-free culture sizes do not correlate blue)/ATP values. Comparison of AMPK activating phosphorylation, PARP cleavage, and ACC inhibitory phosphorylation is shown (D). Cell cycle distribution, mitotic figure counts, S-phase fractions, and culture sizes at day 5 culture in indicated conditions (E). CF, confluent cells in complete media. Day 5 culture sizes differences for high-density versus low-density cultures in glutamine-free media (F). (G) Glutamine consumption (from Figure 1D ) versus glutamine-free culture sizes from (A). (H) hGAC GeneChip hybridization signal versus glutamine-free culture sizes from(A). Green squares on the y axis are the average hGAC hybridization signals from three CD10 + and three BerEP4 + purified normal breast samples. Dotted lines bracket nontumorigenic sample values; C, complete media; Q À , glutamine-free media; and U À , glucose-free media. Icon codes are defined in the figure keys. Icons represent mean values. Error bars represent one standard deviation. See also Figure S2 .
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Glutamine Sensitivity Analysis with glutamine consumption ( Figure 2G , p = 0.13) or hGAC expression ( Figure 2H , p = 0.014). We conclude that historical correlations between these parameters are not applicable to breast tumors.
Restriction Induces S-Phase Stalling in a Subset of TNBC Growth curves of the most restriction-sensitive tumors ( Thus approximately one-half of our TNBC lines are unable to survive or expand without glutamine. We tested whether the few live cells in day 5 group B+C cultures had arrested in G1, reasoning that they might survive glutamine restriction to seed tumor recurrences, discouraging development of glutamine-restricting therapeutics. In complete media, nocodazole treatment increased G2/M and late S-phase fractions of all samples tested, demonstrating transit to and activation of an intact mitotic checkpoint ( Figure 3C , gray bars; late S-phase data not shown; Figure S3B ). Glutamine-free cultures of group A exemplars exhibited similar G2/M increases (gray versus yellow bars), but not group B or C samples. The unchanged S-phase fractions rule out G1 arrest by group B+C samples ( Figure 3D , paired gray versus yellow bars). Their cell cycle profiles are identical with or without nocodazole treatment ( Figure S3C ), indicating S-phase stalling, with reduced total and phosphorylated retinoblastoma proteins similar to S-phase stalling in DNA damage responses ( Figure 3E , Knudsen et al., 2000) . However, like glutamine-restricted Myc-transformed fibroblasts, gH2A.X phosphorylation is not increased, indicating that the intra-S-phase DNA damage checkpoint remains inactive (data not shown; Yuneva et al., 2007) . Culture confluence reduces the S-phase content and glutamine sensitivity of all but two group C samples ( Figure 3F , colored versus gray icons). However, group B+C samples are not simply the most rapidly dividing cells ( Figure 3G ; t tests: all versus C+B, p = 0.11; all basal and claudin low versus C+B, p = 0.2), indicating that they harbor specific defects that make them unable to surmount restriction.
Known Regulators of Glutamine Metabolism Do Not Identify Group B or C Cells
We tested proposals that hGAC and GLUL identified glutaminedependent cells. While hGAC statistically identifies group C (p = 5.6 3 10 À9 ) and group B+C (p = 0.008) cells, only 9/13 (69%) samples expressing higher hGAC than HMECd cells are group B or C ( Figure 4A , above upper dotted line), and these levels are similar to purified normal epithelia (green squares). hGAC also poorly discerns group C (p = 0.03) or B+C (p = 0.17) from all other TNBC. While GLUL levels correlate with restricted culture sizes ( Figure 4B ; p = 0.005-2.3 3 À4 , three probeset IDs; Figure S4A) , GLUL also more accurately discerns luminal from claudin low samples ( Figure 4B ; p = 1.9 3 10 À5 ). At lower p values, GLUL discerns luminal from all basal + claudin low (p = 2.5 3 10 À5 to 1.9 3 10 À4 ), or ER + from ER À (p = 4.4 3 10 À3 to 1.2 3 10 À2 ) cell lines, and samples in seven of eight clinical expression data sets ( Figure 4C ; Table S4 ). Most group B+C cells express less GLUL than normal samples ( Figure 4D) , but low expression is not unique to group B+C (gray circles below lower dotted line). Nor can GLUL discern group C (p = 0.20-0.67) or B+C samples (p = 0.015-0.09) from other TNBC. Thus, hGAC and GLUL are not strong biomarkers for group B or C type tumors.
Oncogenic Myc can drive glutamine uptake and dependence in exemplar fibroblasts and glioma (Wise et al., 2008; Gao et al., 2009; Yuneva et al., 2007) . CMYC is enriched in our basal and claudin low cells (p = 0.013). But neither CMYC, other Myc family members, or core MYC expression signature genes (Chandriani et al., 2009 ) are differentially expressed in group C or group B+C cells versus other basal + claudin low cells ( Figure S4B ; Table  S5 ). We also found no correlation between TP53 mutational status and group B or C membership using the IARC TP53 database (see Supplemental Experimental Procedures, p = 0.7; http://p53.iarc. fr/CellLines.aspx). Significance analysis contrasting gene expression in the group C or B+C samples versus other basal and claudin low TNBC did not identify potential biomarkers or offer molecular explanations for S-phase stalling (data not shown).
Group B and C Carcinomas Are Glutamine Auxotrophs
Glutamine restriction reduces hGAC and GLUL mRNA levels in low-density cultures, while producing little change in GS protein levels ( Figures 4E, 4F , S4C, and S4D). Confluent cultures can induce GLUL mRNA ( Figure 4E , e.g., M435), suggesting one mechanism for their starvation resistance. But we conclude that proliferating breast tumors cannot induce GLUL to escape glutamine restriction.
Titrations of 17 common carbon sources over four concentration logs were tested for rescue of an exemplar group C carcinoma (M436) from glutamine restriction ( Figure S4E ). Neither these nor nitrogen sources, ammonium chloride, choline chloride, or putrescine, improved cultures ( Figure S4F ). Only glutamate (2to 3-fold), oxaloacetate (2%-6%), and dimethyl 2-ketoglutarate (2%-10%; Figure S4G ) increased ATP values slightly; however, only glutamate increased viable cell numbers in multiple group C cell lines (4%-6%; Figure S4H ). Combining GS substrates, glutamate and nitrogen sources, did not further improve cultures ( Figure S4I ). We conclude it unlikely that other commonly available nutrients can substitute for glutamine during restriction, and that the group C+B tumors are functional glutamine auxotrophs. Figure S4 and Tables S4 and S5 . 
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Glutamine Auxotrophy Presents Therapeutic Opportunities
We tested three approaches to therapeutic development targeting auxotrophic TNBC: preventing glutamine access, inhibiting glutamine-dependent enzymes, and inhibiting activities requiring glutamine metabolites. Auxotrophs ( Figure 5A ) and basal carcinoma subsets in clinical microarray data sets ( Figure 5B , example; Table S6 ) express multiple glutamine transporters. Thus we prevented glutamine access by treating cultures with the leukemia therapeutic asparaginase, reducing asparagine and glutamine to their acidic derivatives ( Figure S5A ; Narta et al., 2007) . This produced an apparent synthetic lethality at concentrations equal to that of leukemia in all group C and in approximately one-third of group B cells ( Figure 5C , 85% inhibitory concentration [IC 85 ] below dotted line; Asselin et al., 1989) . Correlated asparaginase sensitivities and glutamine-free culture sizes ( Figure 5D , p = 5.7 3 10 À6 ; asparaginase IC 84 ; p = 9.3 3 10 À9 , not shown) reveal that glutamine re-synthesis from the asparaginase products glutamate and ammonia is uncommon. We propose that local asparaginase/glutaminase delivery would kill auxotrophic tumors without requiring selective identification and targeting of their potentially varied molecular defects. Cells relatively resistant to paclitaxel or doxorubicin are exquisitely asparaginase-sensitive, indicating that an asparaginase-like therapeutic could become a critical, independent alternative for drug-resistant tumors ( Figure 5E ). Analysis of 13 C-5-glutamine-derived metabolites in the group C TNBC M436 ( Figure 5F ; Table S7 ) revealed that 80% of intracellular glutamine is imported (all five carbon positions are 13 Clabeled). Approximately 40% of TCA cycle metabolites and their derivatives are directly produced from this pool, and another one-third (27%-30%) are partially 13 C-labeled. Glutamine restriction depletes these pools ( Figure 5G ), suggesting that inhibition of glutaminase (GLS/hGAC) or aminotrasferases (ATs) might kill or slow growth of the auxotrophs. siRNA-mediated reduction of hGAC-attenuated culture expansion of auxotrophs with high glutamine consumption rates ( Figure 5H, M436, M231; Figure S5B ), but provided little efficacy against BT549, an auxotroph that consumes little glutamine ( Figure 1D ), or H1937, a group A TNBC. In comprehensive tests, treatment with a broad spectrum inhibitor of amidotransferases including GLS (6-diazo-5-oxo-L-norleucine; DON; reviewed in Souba, 1993) placed auxotrophs among the most sensitive samples (Figure 5C ). We propose that inhibitors of single DON targets should be refined for use against auxotrophic TNBC.
Glutamine Is Required for ROS Control in TNBC
Finally, we tested the strategy of inhibiting an activity that requires glutamine metabolites. In the normal human fibroblast IMR-90, one-third of glutamine uptake supplies glutamate for xCT exchange activity (Bannai and Ishii, 1988) . Analysis of amino acid consumption revealed highly correlated cystine depletion and glutamate secretion in 27 of our lines ( Figure 6A , p = 8.8 3 10 À11 ; Figure S6A ), suggesting xCT activity. Glutamine restriction strongly reduced exchange ( Figure 6B ), modestly decreased GSH levels ( Figure 6C ) and increased intracellular ROS by at least 30% in 8/19 TNBC ( Figure 6D, light blue) . This is partially corrected by the ROS scavenger N-acetylcysteine (NAC) in 12/ 13 samples (light gray). NAC does not allow culture expansion ( Figure S6B ), thus, glutamine use for ROS control is common, but other glutamine-influenced factors are also required for auxotroph proliferation.
We directly assessed the xCT expression and function in TNBC that was implied by the glutamine restriction effects on ROS. Basal and claudin low lines overexpress the xCT exchange-specific subunit SLC7A11 (Figure 6E , p = 0.06-7.4 3 10 À4 ; Figure S6C) , the glutamate-cysteine ligase regulatory subunit of glutathione synthase (arrow; GCLM, p = 0.011), and a membrane interacting protein CD44 p = 0.005-5.9 3 10 À8 ; Ishimoto et al., 2011) . Cystine consumption and SLC7A11 mRNA levels correlate ( Figures 6F and S6D) , and siRNA-mediated reduction of SLC7A11 mRNA increases intracellular ROS ( Figures 6G and  6H ). SASP treatment reduces cystine/glutamate exchange and GSH content ( Figures 6B and 6C ). 2-mercaptoethanol (2me) provides cystine as mixed 2me-cysteine disulfides (Ishii et al., 1981) , and normalizes GSH levels, demonstrating SASP specificity for cystine and GSH production. In 18/19 TNBC, SASP increases endogenous ROS by at least 50% ( Figure 6D, teal bars) , which are reduced by NAC in 14/16 samples (dark gray bars). Using reagents for specific ROS species, we found that SASP increases hydroxyl radicals, in keeping with the expected effects of GSH depletion ( Figure S6E ; Franco et al., 2007) . Thus, the xCT antiporter is commonly expressed and functional in TNBC. HMECd expresses these genes ( Figure 6E , columns ''I''), but xCT is much less active ( Figure 6A, green) .
SASP Treatment Attenuates Tumor Growth
In proliferation assays, we found that SASP treatment dramatically reduces TNBC culture sizes with half-maximal inhibitory concentration (IC 50 ) values modestly correlated to cystine uptake in complete media ( Figure 7A , p = 0.07). Culture sizes are significantly restored by NAC ( Figure 7B) and not affected by the active anti-inflammatory fragment of SASP, 5-aminosalicylic acid (5-ASA; Figure S7A ). Thus inhibition of cystine acquisition, not anti-inflammatory activity, is responsible for TNBC proliferative sensitivity. This concentration range (0.2-0.7 mM) is not far from serum concentrations measured in bowel inflammatory patients (0.18 mM; Guastavino et al., 1988) . Under normoxic conditions (5% O 2 ), SASP sensitivity increased 2-to 3-fold (Figure S7B) , and SASP significantly slowed growth of an auxotrophic line xenograft ( Figure 7C ), indicating that xCT activity is also critical for growth in vivo. Accordingly, 8/20 anonymous TNBC clinical specimens strongly express xCT ( Figure 7D and S7C-S7K). TNBC can be treated with carboplatin, and (F) TCA cycle diagram illustrating respiratory use of glutamine in red arrows. Numbers indicate mass spectroscopy determination of the percent of each metabolite that contains (all/several/no) 13 C-carbons derived from culture with 13 C-5-glutamine in M436. H1143  H1937  M468  M175  H1954  H3153  BT20  H100  H1500  H38  M231  M435  M436  BT549 H1569 Hs578t (C) Effects of 24-hr glutamine restriction or SASP treatment on GSH content in an exemplar group C TNBC; Q, glutamine-free media; SASP, SASP treatment in complete media; and SASP + 2me, SASP treatment in the presence of beta-mercaptoethanol.
(D) ROS levels in basal carcinomas assessed with DCFHDA fluorescence, normalized to control media reactivity. Light blue, 2-day cultures in glutaminefree media. Group averages: A, 112% ± 21; B, 121% ± 31; C, 162% ± 59; t test group A versus C, p = 0.07; and group A versus B+C, p = 0.074. Light gray, (legend continued on next page) carboplatin + SASP reduces the carboplatin IC 50 in 13/14 of our TNBC samples ( Figure 7E ). We propose that SASP be derived for clinical use.
DISCUSSION
Rodent breast tumors (Erlich Ascites series) were instrumental in the definition of central metabolic pathways and tumor-specific aberrations, but work in human breast tumors is largely limited to aspects of fatty acid metabolism (see Menendez and Lupu, 2007) . Reports of other metabolic features are less frequent and use only one or a few samples, producing biased conclusions due, for example, to the mistaken use claudin low lines to represent typical TNBC; misidentification of GeneChip probeset IDs that are hGAC splice variant specific as reporting total GLS mRNA; the lack of gene expression comparisons between tumors and normal breast epithelia; and the inability to directly compare nontumorigenic breast derivative and tumorigenic behaviors (for examples, see Collins et al., 1998; Kung et al., 2011; Simpson et al., 2012) . Our data clarify these misunderstandings and provide a detailed nutrient utilization portrait of a comprehensive organ site-specific tumor collection, contrasting gene expression and functional assays to define common nutrient utilization patterns and responses to drugs that leverage associated metabolic activities.
Historically Associated Metabolic Features Vary Substantially in Breast Cancer
Doubling time, glutamine consumption, and glutamine reliance are historically correlated. Among this triad, only doubling time and glutamine-free culture sizes modestly correlate across our large sample collection ( Figure 3G , p = 0.002). However, the glutamine auxotrophs are not simply the most rapidly dividing samples. Nor are they the largest glutamine consumers; four of eight auxotrophic, claudin low samples consume no more glutamine than proliferating nontumorigenic cells ( Figure 1D , black triangles: BT549, H38, H100, M157). Glutamine can be cycled by import via ASCT2 and export in exchange for essential amino acids via the LAT1/4f2hc antiporter (SLC7A5/SLC3A2, Figure 7F , dark blue arrows; Nicklin et al., 2009 ). Our four low glutamine consumers express all antiporter components ( Figure 5A ), and glutamate cycling would not deplete measured ambient glutamine levels. Thus, these cells may require glutamine to fuel both this exchange activity and the xCT antiporter and use relatively less glutamine for respiration. This may explain the relative proliferative resistance to siRNA-mediated reduction of hGAC seen in BT549 ( Figure 5H ). Differences between glutamine cycling and catabolism may also partially explain historically variable correlations between glutamine uptake and glutamine reliance in other tumors.
Conversely, auxotrophs of high glutamine consumption (Figure 1D ; M436) that require glutamine as a major respiratory fuel ( Figures 5F and 5G ; Figure 7F , light blue arrows) and for glutamate/cystine exchange ( Figures 6B and 7F, gray arrows) , may be more susceptible to inhibition of hGAC ( Figure 5H ; M436, M231) and subordinate glutamate-dependent activities such as aminotransferases (ATs; Thornburg et al., 2008) . Thus within a single tumor cell line, multiple critical requirements for glutamine may exist and provide multiple therapeutic targets, either individually or in combination. We hypothesize that xCT inhibition may be further potentiated by limiting glutamate availability ( Figure 7F ).
Historically Proposed Genetic Indicators of Glutamine Reliance Do Not Define Auxotrophy
With the resurgent interest in tumor metabolism, metabolic genes such as GLS and GLUL have been re-asserted as potential therapeutic targets and biomarkers, but we find that therapeutic relevance is not so easily defined. Gene expression may suggest metabolic behaviors that are more likely active in specific tumor groups, such as a statistical association of hGAC with high glutamine consumption in basal and claudin low versus luminal tumors ( Figures 1F) . However, neither hGAC nor GLUL defines high glutamine consumption or identifies the true auxotrophic group B and/or C cells with appropriate sensitivity to be considered independent clinical biomarkers. We also find that responses to interruption of ongoing metabolic activities can vary substantially due to unknown cell-intrinsic factors. For example, individual tumors can respond to glutamine restriction by slowing culture expansion or stalling in S-phase and dying ( Figures 3A-3C ). Molecular explanation(s) for S-phase stalling remain unclear and may be due to tumor defects far removed from direct glutamine interaction.
xCT Is a Compelling Therapeutic Target for Triple-Negative Tumors Inhibitor and RNAi studies reveal xCT induction as the dominant means of increasing cystine acquisition to accelerate GSH synthesis (reviewed in Lo et al., 2008a) . Thus xCT may be a target for cell-specific GSH depletion, because SASP and other xCT inhibitors can slow growth of exemplar cell lines in xenograft without significant effects on other organs and can cooperate with chemotherapeutics such as cisplatin (Okuno et al., 2003) , geldanamycin (Huang et al., 2005) , doxorubicin (Narang et al., 2007) , and gemcitabine (Lo et al., 2008b) . Currently, the SASP structure is labile, designed to be cleaved by enteric bacteria to release an active anti-inflammatory fragment. It is also insoluble in aqueous solutions and not optimized for the fortuitous interaction with xCT. Thus while direct clinical applications to TNBC are unrealistic, SASP is a strong lead compound for development of xCT glutamine-free media +NAC. Teal, cultures treated 24 hr with SASP. Group averages; A, 205% ± 43; B, 287% ± 62; C, 405% ± 168; t test group A versus C, p = 0.019; and group A versus B+C, p = 0.003. Dark gray, SASP +NAC. 6A, 6E , and 7D), and deleterious proliferative effects of xCT inhibition are common in basal and claudin low carcinomas ( Figures 7A and  7C) . CD44 and the claudin low gene expression signature associate with breast cancer stem-cell phenotypes (Hennessy et al., 2009 , Prat et al., 2010 , implying that SASP-derived therapeutics may target breast tumor stem cells. This is reminiscent of CD44 and xCT-dependent ROS regulation in gastric tumor progenitors (Ishimoto et al., 2011 
Glucose Uptake
Cultures in Dulbecco's modified Eagle's medium/low glucose (GIBCO 11885), RPMI, or HMEC (Medium 171, Cascade Biologics), were treated with or without 2-NBDG or 6-NBDG glucose (30 mM, Molecular Probes N13195, N23106) for 0-8 hr, harvested, external fluorescence quenched (0.4% trypan blue), and 30,000 cells analyzed in triplicate FACSCalibur (Becton Dickinson) or C6 Flow Cytometer (Accuri). Average mean fluorescence values at 4 hr normalized to unstained controls are reported as ± SD.
ROS Detection
Cells were incubated for 15 min with 10 mM 2 0 ,7 0 -dichlorofluorescein diacetate (DCFH-DA, Sigma D6883), or 1 hr with 5 mM 3 0 -(p-hydroxyphenyl) fluorescein (HPF, Molecular Probes H36004), harvested, and 30,000 cells analyzed in triplicate by FACS, normalized to unstained controls. Average mean fluorescence values are reported as ± SD.
GSH Quantitation
We used the ApoGSH Glutathione Detection Kit (BioVision) per manufacturer's instructions in triplicate with 2-me at 60 mM. Average values are reported as ± SD.
Amino Acid Analysis
Supernatants from 24-hr subconfluent duplicate or triplicate cultures and cell-free media were analyzed using standard high-performance liquid chromatography (HPLC) techniques (Biochemical Genetics Laboratory, Stanford University; UC Davis Genome Center, UC Davis). Values were subtracted from media controls, normalized to cell number. Average values are reported as ± SD.
Metabolite Analysis
Cells were cultured in the presence of 13 C-5 labeled glutamine (Cambridge Isotope) for 0-12 hr, PBS washed, frozen (dry ice), lyophilized, pellets weighed, and homogenized in cold 60% acetonitrile (40 ml per 1 mg of protein with acetonitrile-washed glass beads). Samples were incubated for 30 min at À80 C, supernatants collected, and pellets washed (60% acetonitrile). Pooled supernatants were lyophilized, resuspended in 200 ml H 2 0, and 40 ml mixed with 30 ml of 40% TCA and 50 ml of 0.1 mM noreleucine (Sigma; internal standard). Lyophilized samples were silylated (50 ml acetonitrile: MTBSTFA; N-methyl-N-tert-butyl-dimethylsilyltrifluoroacetamide, Regis Chemical, Morton Grove, IL, v/v 1:1), sonicated for 3 hr, and incubated overnight. Analysis used a PolarisQ GC-ion trap mass spectrometer (ThermoFinnigan, Austin, TX) as previously described (Yuneva et al., 2012) . Metabolites were identified and quantitated using XCalibur software (ThermoFinnigan). Results were normalized to dry pellet weight, and noreleucine standard. Average values are reported as ± SD.
Immunohistochemistry
Cell lines and anonymous, de-identified tumor sections (UCSF/SPORE Tissue Core, collected under UCSF Internal Review Board approval) with high and low SLC7A11 values , were stained to correlate anti-xCT reactivity (Novus Biologicals NB300-318) with SLC7A11 mRNA levels (data not shown). Detection used citrate antigen retrieval, ABC Kit (Vector Labs), and the Novus antibody-specific protocol. Commercial tissue arrays of anonymous breast tumor and normal sections with known ER/PR/Her2 status were purchased and analyzed (Biomax).
Bioinformatics
Association of GLS and GLUL expression with ER status and molecular subtype was determined in clinical microarrays available at http://www.ncbi. nlm.nih.gov/gds. Data were preprocessed (RMA algorithm in R), and analyzed with Matlab R2011a and R version 2.12.0 for MacOS X. Pearson correlations are reported; class distinctions by Student's t test.
Xenografts
The claudin low auxotroph M231 was implanted into mammary fatpad 4 in fourteen 6-week-old NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ) female mice. Animals were randomized at day 16 and injected intraperitoneally twice daily with 250 ml saline or 50 mM SASP in 0.1 N NaOH pH 7.5 from days 17 to 31 (Guan et al., 2009) . Tumor volume was measured twice weekly,and average values reported as ±SD. Experiments performed following UCSF Institutional Animal Care and Use Committee approval, in accordance with institutional and national guidelines.
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